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Dexmedetomidine (DEX), a highly selective α2-adrenergic receptor agonist, is the newest agent introduced for 
sedation in intensive care unit (ICU). The sedation strategy for critically ill patients has stressed light sedation with 
daily awakening and assessment for neurologic, cognitive, and respiratory functions, since Society of Critical Care 
Medicine (SCCM) guidelines were presented in 2002. The traditional GABAergic agents, including benzodiazepines 
and propofol, have some limitations for safe sedatives in this setting, due to an unfavorable pharmacokinetic profile 
and to detrimental adverse effects (such as lorazepam associated propylene glycol intoxication and propofol infusion 
syndrome). DEX produces it's sedative, analgesic and cardiovascular effects through α2 receptors on the locus 
ceruleus (LC). Activities of LC, the tuberomammillary nucleus (TMN) are depressed and activity of the ventrolateral 
preoptic nucleus (VLPO) is increased during DEX sedation, which is similar in features to normal non-REM (NREM) 
sleep. At the same time, perifornical orexinergic activity is maintained, which might be associated with attention. 
This mechanism of action produces a normal sleep-like, cooperative sedation. The characteristic feature of sedation, 
together with a concomitant opioid sparing effect, may decrease the length of time spent on a ventilator, length of 
stay in ICU, and prevalence and duration of delirium, as the evidence shown from several comparative studies. In 
addition, DEX has an excellent safety profile. In conclusion, DEX is considered as a promising agent optimized for 
sedation in ICU. (Korean J Anesthesiol 2012; 62: 405-411)
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Introduction
Dexmedetomidine (DEX), the newest sedative, is a highly 
selective α2-adrenergic receptor agonist having different 
mechanism from traditional agents (benzodiazepine [BDZ], 
propofol) which act on the GABA receptor. There are subtypes 
of α2-adrenergic receptor, which include α2A, α2B, α2C; DEX seems 
to produce its therapeutic effects primarily through the α2A 
receptor [1,2]. 
A number of studies have been undertaken to evaluate 
the efficacy and availability of DEX in various clinical fields 
including sedation for critically ill patients, adjuvant for general 
and regional anesthesia, monitored anesthesia care for some 
invasive procedures, postoperative analgesia, stabilization 
of heart in cardiac surgery or procedures, since its approval 406 www.ekja.org
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by the FDA in 1999 [3-5]. Among these, especially in the area 
of sedation in ICU, DEX is expected to play a role in relation 
to its unique features of action. The sedative strategy for 
critically ill patients has emphasized light sedation with daily 
awakening and assessment for neurologic, cognitive, and 
respiratory functions, since SCCM guidelines were presented 
in 2002 and concerns on adverse effects associated with 
oversedation emerged [6-8]. However, traditional sedatives 
have some limitations as safe drugs for this strategy due to 
their unfavorable pharmacokinetic [9] or detrimental adverse 
effects that include lorazepam-associated propylene glycol 
intoxication [10] and propofol infusion syndrome [11]. Thus, 
there are growing interests on DEX as a possible alternative.
This paper will review the distinctive pharmacologic features 
of DEX in regard to the 2002 SCCM guidelines on sedation 
and analgesia in ICU, which will be reviewed. In addition, its 
advantages and safety as ideal alternative of current sedatives 
will be elucidated through literature review.
Summary of 2002 SCCM Guidelines for the 
Sustained Use of Sedatives and Analgesics 
in the Critically Ill Adult [6]
Analgesia 
The level of pain and response to treatment should be 
assessed regularly and documented systematically by use of an 
adequate scale.
Fentanyl, hydromorphone, and morphine are the recom-
mended opioids for intravenous use, and scheduled or con-
tinuous infusion is preferred over an “as needed” regimen.
Pharmacokinetic characteristics should be considered for 
selection of drug and regimen.
Sedation 
Sedation of agitated patients should be started only after 
providing adequate analgesia and treating reversible physio-
logical causes.
A sedation goal should be established and regularly rede-
fined for each patient.
The use of a validated sedation assessment scale (SAS [12], 
MAAS [13], or VICS [14]) is recommended.
Selection of sedatives should be done considering pharma-
co  kinetic and pharmacodynamic properties among midazolam, 
diazepam, lorazepam, and propofol. 
The titration of the sedative dose to a defined goal is recom-
mended, with systematic tapering of the dose or daily interrup-
tion with re-titration to minimize prolonged sedative effects. 
The use of sedation guidelines, an algorithm, or a protocol is 
recommended.
Sedative and analgesic withdrawal
Doses should be tapered systematically to prevent withdrawal 
symptoms after high doses or more than approximately seven 
days of continuous therapy with opioid, BDZ, and propofol.
Delirium
Routine assessment for the presence of delirium is recom-
mended (The Confusion Assessment Method for the Intensive 
Care Unit [CAM-ICU] [15] is a promising tool).
Haloperidol is the preferred agent for delirium, and requires 
electrocardiographic monitoring during its use. 
Sleep
Sleep promotion should include optimization of the environ-
ment and nonpharmacologic methods to promote relaxation 
with adjunctive use of hypnotics.
Characteristic Pharmacology of DEX in the 
ICU Setting 
The primary site of action in the brain for DEX is the locus 
ceruleus (LC) [16]. LC plays a key role in regulation of arousal 
and autonomic activity through numerous projections to 
multiple sites, including the sleep promoting nucleus and 
autonomic nucleuses [17]. Inhibition of norepinephrine (NE) 
release from LC by DEX depresses alertness and sympathetic 
activity, which present sedation, hypotension (Transient hyper-
tension may develop following high dose of DEX through 
activation of peripheral vascular α2B receptor.), bradycardia, 
decreased cardiac output [16,18], and spinal cord mediated 
analgesia [19]. 
Analgesic effect
DEX has both sedative and analgesic effects, unlikely other 
sedatives. The antinociceptive effect of intrathecal DEX is 
relatively well described as the previously introduced α2 agonist, 
clonidine [20]. The mechanism of action is considered to be 
through the α2A and α2C receptors on presynaptic C-fiber and 
postsynaptic spinal dorsal horn neuron [21,22]. Intrathecal 
DEX prolongs duration of motor and sensory blockade by local 
anesthetics more than twice, and decreases maximum VAS, 
which effect is stronger than fentanyl [23-25]. 
In contrast, there is controversy over analgesia with systemic 
administration. Intravenous DEX prolongs and potentiates local 407 www.ekja.org
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anesthetic action that had been administrated intrathecally 
[26,27]; however, it is not evident that DEX has consistent and 
dose-dependent analgesia against various nociceptive stimuli 
[19-29]. Rather, DEX has notable effects to increase the potency 
or reduce requirement of analgesics as an adjunctive. It appears 
to reduce the requirement for morphine by as much as 66% 
after major operations [30-32]. The opioid sparing effect of DEX 
reduces respiratory depression by opioid, and this could be 
helpful for patients who breathe spontaneously or are being 
weaned from a ventilator.
Sedative effect
DEX induces a unique state called “cooperative sedation” . 
This may be associated with the orexinergic perifornical nucleus 
activity is maintained with DEX, but not with GABAergic 
sedatives, which is thought to be connected to attention [33,34]. 
As a result, DEX could enable critically ill patients to do well 
with daily awakening for assessment of sedation, analgesia, 
neurologic and respiratory function, which is considered 
essential to reduce ventilatory support and to improve outcomes. 
However, we could find these guidelines are not followed 
by current ICU care for recent observational studies. In a study 
which observed 1,381 patients from 44 ICUs, Payen et al. [35] 
reported that the assessment of sedation (43%) and analgesia 
(42%) was much less than use of sedative (72%) and opioids 
(90%), and as many as 40-50% of patients were deeply sedated. 
Another study, which was conducted in a university associated 
ICU, revealed that unarousable deep sedation occupied 32% 
of total observation, but only 2.6% of assessment was recorded 
as oversedation [36]. These results show that many healthcare 
givers still recognize deep sedation as adequate sedation, and 
this concept may be associated with that familiar sedative 
character of frequently used drugs as adequate. In addition, it 
has been noted that the administration of BDZ leads to more 
frequent oversedation in ICU [37]. To alter the paradigm of 
sedation for critically ill patients, an alternative drug with 
optimized pharmacologic features should be available, as well 
as changes in the medical staffs’ understanding and protocol-
guided medical practice. 
According to several comparative studies, DEX is observed 
to improve some therapeutic outcomes including the goal of 
achieved sedation, the duration of ventilatory care, and the 
length of stay (LOS) in ICU. 
Dex vs. Midazolam
DEX significantly reduced LOS in ICU (45.5 hours vs. 83 
hours), duration from stop of drug to discharge from ICU (21 
hours vs. 52 hours), and requirement of antihypertensive drug 
(less than 50%) with decreased heart rate and mean arterial 
pressure in 24 hours, in eclampsia patients [38]. 
The Safety and Efficacy of Dexmedetomidine Compared with 
Midazolam (SEDCOM) study presents that DEX was associated 
with shorter median time to extubation by 1.9 days (3.7 days vs. 
5.6 days; P = 0.01) compared to midazolam, but LOS in ICU (5.9 
days vs. 7.6 days; P = 0.24) and time within target Richmond 
Agitation-Sedation Scale [RASS] [39] score range (77.3% vs. 
75.1%; P = 0.18) was similar between 2 drugs [40]. 
Dex vs. Lorazepam
The Maximizing Efficacy of Targeted Sedation and Reducing 
Neurological Dysfunction (MENDS) study resulted in better 
sedative efficacy (RASS within 1 point of goal 80% vs. 67%; P = 
0.04) with less likelihood of oversedation (15% vs. 33%) in the 
DEX group than in the lorazepam group [41]. 
Dex vs. Propofol
DEX provided adequate sedation com  parable to propofol for 
postoperative ventilator care of patients with extensive cervical 
spinal operation [42].
In a study that evaluated sedative efficacy of DEX compared 
to standard therapy with propofol or midazolam, both drugs 
showed similar adequacy to light to moderate sedation (RASS 0 
to -3). However, sedation by DEX was unreliable when deeper 
sedation (RASS score of -4 or less) is targeted (time at target 
RASS 42% vs. 62%; P = 0.06) [43]. 
Collectively, though data are not identical with each other, 
DEX produces better or at least, similar sedative adequacy 
compared to traditional agents and has potential to decrease 
the duration of ventilatory care and LOS in ICU. It could provide 
patients under the risk of hypertensive crisis or tachycardia, 
with more hemodynamic stability. However, in the case of a 
required deep level of sedation around a RASS score -4, DEX 
might be an inappropriate option, so other agents or use with 
additive drugs should be considered. 
Withdrawal
Most of studies reported no withdrawal symptoms even 
following abrupt discontinuation of DEX, but still there 
was a small possibility of developing agitation, headache, 
hyperhidrosis, tremor, nausea, vomiting in minor population 
[40], so a progressive tapering is considered safe.
Unlike clonidine, DEX does not produce rebound hyper-
tension nor tachycardia after prolonged infusion [44,45]. 
Delirium
Delirium is an acute neuropsychiatric syndrome of attentional 
deficit, disorganized thought, cognitive dysfunction with 408 www.ekja.org
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fluctuating course and it is reported to affect up to 80% of 
patients in ICU [6]. Management of delirium is so important 
in critical care because it is directly associated with patients 
outcome. Delirium is now designated for the strongest 
independent predictor of mortality, duration of ventilatory care, 
LOS in ICU, and total duration of hospital admission [40,46,47]. 
The causes that develop or precipitate delirium include 
sedatives [47,48]. The GABAergic agents cause cognitive 
impair  ment through direct effect on memory formation and 
modulation, or indirect sleep disturbance [34]. The normal 
process of memory involves both slow wave sleep (stage 3,4 of 
NREM sleep) and REM sleep [49]. BDZ alters sleep architecture 
and depresses slow wave sleep [50]. On the contrary, DEX has 
little effect on direct memory impairment [28], and preserves 
slow wave sleep [34,51]. Thus, it has less influence on cognitive 
dysfunction. This character is accompanied by arousability, 
facilitates cooperative assessment for delirium and would be 
advantageous to prevention and diagnosis of delirium. 
There is the clinical evidence for DEX’s effect on prevention 
of delirium. Coming 2 studies have high confidence in that daily 
arousal with assessment for delirium using CAM-ICU once or 
twice daily was performed to objective patients. SEDCOM study 
showed lower prevalence of delirium in the DEX group than in 
the midazolam group (54% vs. 76.6%; P < 0.001) [40]. MENDS 
study measured the number of days alive without delirium or 
coma, presenting a higher value in the DEX group (7.0 days vs. 
3.0 days; P = 0.01) and lower prevalence of coma as well (63% vs. 
92%; P < 0.001) than in the lorazepam group [41]. These results 
show that DEX is superior to BDZ in prevention of delirium or 
coma. 
However, the effect of DEX on delirium, in spite of its favo-
rable pharmacologic distinction with clinical evidence, has 
not been proven to be significantly different from traditional 
sedatives in a meta-analysis that included 2,419 patients that 
participated in 24 trials [52]. This does not mean that DEX has 
no benefit, considering limitations of significant heterogeneity 
and inconsistent measurement of delirium between the pooled 
studies. 
DEX seems to have a therapeutic potential on delirium, as 
well as on prevention. There is an interesting preliminary trial, 
though it is limited by small sample size, in which 20 patients 
who could not be weaned from a ventilator because of agitated 
delirium were treated with DEX or haloperidol [53]. Results 
showed that the DEX group had a markedly shorter time to 
extubation (19.9 hours vs. 42.5 hours; P = 0.016) and ICU LOS 
(1.5 days vs. 6.5 days; P = 0.004) as well. Because the duration 
of ventilatory support and ICU stay are definitely related to a 
reduction in delirium, particularly in this trial, results reflect 
the influence of DEX on delirium directly. Considering that 
haloperidol is preferentially recommended drug for treatment 
of delirium now, this study has great significance. DEX needs 
further evaluation with respect to preventive and therapeutic 
effect on delirium through large, well designed study with 
definitive measuring protocol and encouraging prospect is 
expected in this field. 
Sleep preserving or mimicking effect
The sleep deprivation or fragmentation frequently occurring 
in ICU results in various physiological changes that include 
immune, metabolic, and endocrine function, all of which 
precipitate delirium [34,54]. The arousal and sleep is a com-
plicated process that is regulated by the interactions between 
multiple sites in the brain. 
Alertness is increased by the arousal promoting neuro-
transmitters - NE, serotonin, histamine, acetylcholine, orexin - 
released from activated LC, dorsal raphe nucleus, tubero-
ma    mmillary nucleus (TMN) acting on the cortex, forebrain, 
and subcortical area. Meanwhile, sleep is promoted when 
these activities are reversed by inhibitory action of GABA and 
galanin from activated ventrolateral preoptic nucleus (VLPO) 
[55]. During normal NREM sleep, activities of the LC and 
TMN are depressed and that of VLPO is increased, which is 
observed similarly in DEX sedation [33,56]. But, in sedation 
with GABAergic agents, increased activity of VLPO depresses 
TMN, yet spared LC activity is maintained [33]. Accordingly, 
unchanged noradrenergic activity of LC despite an activated 
sleep promoting pathway may induce “restless” sleep [2,56]. 
The evidence for DEX’s normal sleep preserving effect is 
supported with electroencephalographic (EEG) finding [51,56]. 
DEX is definitely more physiologic than other sedatives which 
inhibit spontaneous sleep, and further investigation should be 
proceeded to decide what effect this would have on specific 
therapeutic outcome in the critically ill patient. 
Pharmacokinetics, adverse effects and safety
DEX has an onset of action approximately in 15 minutes 
after intravenous injection, and reaches its peak concentration 
after 1 hour of continuous infusion. It has distribution half-life 
of 6 minutes and terminal elimination half-life of 2 to 2.5 hours. 
It is usually highly protein-bound, so only 6% of drug remains 
free, with relatively large steady state volume of distribution (Vdss, 
1.33 L/kg). DEX is extensively metabolized through glucuronide 
conjugation and cytochrome P450 biotransformation in liver 
with no proven active or toxic metabolites [2]. Clearance may 
be decreased as much as 50% with severe hepatic dysfunction. 
In severe renal disease, pharmacokinetics are usually preserved 
except for an increase in Vdss, but sedation may be prolonged. 
To prevent unwanted prolonged sedation, dosage should be 409 www.ekja.org
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decreased in patients with hepatic or renal disease, hypoal-
buminemia, decreases cardiac output, and elderly patients 
[2,57,58]. 
Depressed sympathetic activity with DEX decreases catechola-
mine in a dose-dependent manner, which subsequently causes 
a decrease in heart rate and cardiac output. But mean arterial 
pressure, pulmonary arterial pressure, and vascular resistance 
show biphasic response of initial decrease and later increase 
with dose-escalation. Stroke volume is well preserved until the 
DEX concentration is high, but cardiac output declines due 
to bradycardia [28]. This cardiovascular effect following DEX 
treatment would prevent hypertension and tachycardia or 
decrease requirements for antihypertensives [38,40]. However, 
it might be harmful to hemodynamically unstable patients.
Most studies consistently pointed out bradycardia as the only 
adverse effect of DEX. Actually, DEX does not increase the risk of 
bradycardia in general, but only in cases with both a loading dose 
and high maintenance dose (> 0.7 μg/kg/h) are administrated, 
and furthermore, it does not seem to be associated with 
increased risk of significant hypotension requiring treatment 
[52]. Even if bradycardia has developed, it is reversed with 
relatively simple intervention, such as by decreasing the dose 
[40]. More seriously, asystole has developed in some cases, 
mostly when concomitant sympathetic inhibitors or cholinergic 
drugs are given for surgery or procedure, particularly with 
vagal nervous stimulation (eg, sternal separation, colonoscopy) 
applied, and in most cases, normal sinus rhythm is restored with 
discontinuation of DEX [59-61].
The recommended dose for sedation in ICU, is a loading dose 
of 1 μg/kg over 10 minutes followed by continuous infusion of 
0.2-0.7 μg/kg/h (< 24 h). However, several trials have used a 
higher dose up to 1.5 μg/kg/h over 24 hours, without clinically 
significant problems [40,41,43-45]. Actually, DEX has excellent 
safety considering there were no adverse effects, except for 
oversedation in the cases of accidentally overdose of 2.5 to 60 
times of intended dosages [62].
However, there still is a long way to go to extend all the bene-
fits of DEX to the general population of critically ill patients. 
Several studies have limitations of that exclude many disease 
groups - neurologic disease, acute MI, heart block, trauma, burn 
injury, serious CNS pathology, severe liver disease, pregnancy - 
from clinical trials or small sample size or being unblinded [45]. 
Conclusion
DEX preserves a natural sleep pattern and induces coopera-
tive sedation in which patients are easily arousable, leads to less 
impairment in cognitive function, and has an opioid sparing 
effect as well. If daily arousal and appropriate assessment for 
sedation and delirium are performed routinely, DEX decreases 
duration of ventilatory care, ICU stay, prevalence, and duration 
of delirium with better adequacy of sedation, and therefore 
improvement in outcomes. DEX is a promising sedative optimized 
for ICU care. 
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